US20150216807A1 - Solubilized coq-10 - Google Patents
Solubilized coq-10 Download PDFInfo
- Publication number
- US20150216807A1 US20150216807A1 US14/565,679 US201414565679A US2015216807A1 US 20150216807 A1 US20150216807 A1 US 20150216807A1 US 201414565679 A US201414565679 A US 201414565679A US 2015216807 A1 US2015216807 A1 US 2015216807A1
- Authority
- US
- United States
- Prior art keywords
- composition
- coq
- coenzyme
- monoterpene
- soft gelatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Definitions
- the present invention relates to the solubilization of coenzyme Q-10 and analogs thereof in monoterpenes, thereby providing increased bioavailability in delivery.
- CoQ-10 (coenzyme Q10) is a fat-soluble quinone that is structurally similar to vitamin K and commonly known as ubiquinone. CoQ-10 is found in most living organisms, and is essential for the production of cellular energy. CoQ-10 (2,3 dimethyl-5 methyl-6-decaprenyl benzoquinone) is an endogenous antioxidant found in small amounts in meats and seafood. Although CoQ-10 is found in all human cells, the highest concentrations of CoQ-10 occur in the heart, liver, kidneys, and pancreas. It is found naturally in the organs of many mammalian species.
- CoQ-10 can be synthesized in the body or it can be derived from dietary sources. Situations may arise, however, when the need for CoQ-10 surpasses the body's ability to synthesize it. CoQ-10 can be absorbed by oral supplementation as evidenced by significant increases in serum CoQ-10 levels after supplementation.
- CoQ-10 is an important nutrient because it lies within the membrane of a cell organelle called the mitochondria. Mitochondria are known as the “power house” of the cell because of their ability to produce cellular energy, or ATP, by shuttling protons derived from nutrient breakdown through the process of aerobic (oxygen) metabolism. CoQ-10 also has a secondary role as an antioxidant. CoQ-10, due to the involvement in ATP synthesis, affects the function of almost all cells in the body, making it essential for the health of all human tissues and organs. CoQ-10 particularly effects the cells that are the most metabolically active: heart, immune system, gingiva, and gastric mucosa
- CoQ-10 has been shown to be effective in supporting blood pressure and cholesterol levels. Furthermore, CoQ-10 has also been shown to improve cardiovascular health. CoQ-10 has been implicated as being an essential component in thwarting various diseases such as certain types of cancers. These facts lead many to believe that CoQ-10 supplementation is vital to an individual's well being.
- CoQ-10 is sparingly soluble in most hydrophilic solvents such as water. Therefore, CoQ-10 is often administered in a powdered form, as in a tablet or as a suspension. However, delivery of CoQ-10 by these methods limits the bioavailability of the material to the individual.
- the present invention pertains to the surprising discovery that ubiquinone (CoQ-10) can be readily dissolved in varying concentrations in monoterpenes. Generally, until the present discovery, most CoQ-10 liquid delivery methods could solubilize only up to about 5% by weight of the CoQ-10 in the “solvent”. Typical solvents included various oils or the CoQ-10 was held in suspension.
- the present invention provides the ability to solubilize CoQ-10 in monoterpenes in concentrations of up to about 60% (weight to weight) without the need to aggressively heat the solution or with gentle warming. In particular, the solubilization of the CoQ-10 with monoterpenes can be accomplished at ambient temperatures.
- the present invention pertains to compositions that include coenzyme Q-10 or an analog thereof with a sufficient quantity of a monoterpene that is suitable to solubilize said coenzyme Q-10 and a pharmaceutically acceptable carrier.
- a monoterpene that is suitable to solubilize said coenzyme Q-10 and a pharmaceutically acceptable carrier.
- the monoterpene is limonene.
- the compositions of the invention are useful as dietary supplements or as nutriceuticals.
- compositions of the invention are included in a soft gelatin (soft gel) capsule.
- the soft gelatin capsule includes at least 5% by weight of coenzyme Q-10 or an analog thereof solubilized in a monoterpene.
- monoterpenes include, for example, perillyl alcohol, perillic acid, cis-dihydroperillic acid, trans-dihydroperillic acid, methyl esters of perillic acid, methyl esters of dihydroperillic acid, limonene-2-diol, uroterpenol, and combinations thereof.
- the present invention pertains to methods for delivery of an effective amount of bioavailable CoQ-10 to an individual.
- the method includes providing CoQ-10 solubilized in a monoterpene, such that an effective amount of CoQ-10 is provided to the individual.
- the present invention also includes packaged formulations of the invention that include a monoterpene as a solvent for the CoQ-10 and instructions for use of the tablet, capsule, elixir, etc.
- the present invention pertains to the surprising discovery that ubiquinone (CoQ-10) can be readily dissolved in varying concentrations in monoterpenes.
- CoQ-10 is found in most living organisms, and is essential for the production of cellular energy.
- Ubiquinone is a naturally occurring hydrogen carrier in the respiratory chain (coenzyme Q) and structurally, it is a 2,3-dimethoxy-5-methyl-1,4-benzoquinone with a multiprenyl side chain, the number of isoprene units varying depending upon the organism from which it is derived.
- CoQ-10 analogs include reduced and semi-reduced CoQ-10 and ubiquinone derivatives described, for example, in WO 8803015, the teachings of which are incorporated herein by reference.
- CoQ-10 liquid delivery methods could solubilize only up at most about 10% by weight of the CoQ-10 in the “solvent.
- Typical solvents included oils or the CoQ-10 was held in an aqueous suspension.
- the CoQ-10 was provided as a solid in a tablet or powder.
- the present invention provides the ability to solubilize CoQ-10 in monoterpenes, as defined herein, in concentrations of up to about 60% (weight to weight) without the need to heat the solution.
- the monoterpene solubilizes CoQ-10 from about 0.1 percent by weight to about 45 percent by weight.
- the solubilization of the CoQ-10 with monoterpenes can be accomplished at ambient temperatures.
- from about 5 to about 50 percent (weight CoQ-10/weight solvent) CoQ-10 can be solubilized in a monoterpene.
- from about 15 to about 40 percent w/w can be solubilized and in still another aspect, from about 20 to about 35 percent w/w CoQ-10 can be solubilized in a monoterpene.
- sufficient quantity of a monoterpene suitable to solubilize coenzyme Q-10 is therefore intended to mean that that amount of a monoterpene that will dissolve CoQ-10 under a given set of conditions, generally, those at ambient temperature. This determination should be understood by one skilled in the art and can be determined by methods known in the art, such as by solubility studies.
- One of the particular advantages of utilizing monoterpenes in combination with CoQ-10 is that the enzyme is dissolved by the monoterpene. That is, many formulations currently in the marketplace have CoQ-10 present as a suspension; a situation where not all the CoQ-10 is dissolved. This reduces efficacy and the bioavailability of the CoQ-10.
- the present invention eliminates this disadvantage by solubilizing the CoQ-10 in the monoterpene.
- a particular advantage in using monoterpenes is that the CoQ-10 does not have to be heated to dissolve into solution. This is important so that the CoQ-10 does not degrade upon dissolution.
- monoterpene refers to a compound having a 10-carbon skeleton with non-linear branches.
- a monoterpene refers to a compound with two isoprene units connected in a head-to-end manner.
- the term “monoterpene” is also intended to include “monoterpenoid”, which refers to a monoterpene-like substance and may be used loosely herein to refer collectively to monoterpenoid derivatives as well as monoterpenoid analogs.
- Monoterpenoids can therefore include monoterpenes, alcohols, ketones, aldehydes, ethers, acids, hydrocarbons without an oxygen functional group, and so forth.
- Suitable examples of monoterpenes include, but are not limited to, limonene, pinene, cintronellol, terpinene, nerol, menthane, carveol, S-linalool, safrol, cinnamic acid, apiol, geraniol, thymol, citral, carvone, camphor, etc. and derivatives thereof.
- limonene pinene
- cintronellol terpinene
- nerol terpinene
- menthane carveol
- S-linalool safrol
- cinnamic acid apiol, geraniol, thymol, citral, carvone, camphor, etc.
- terpenes of the invention see Kirk-Othmer Encyclopedia of Chemical Technology, Mark, et al., eds., 22:709-762 3d Ed (1983), the teachings of
- suitable limonene derivatives include perillyl alcohol, perillic acid, cis-dihydroperillic acid, trans-dihydroperillic acid, methyl esters of perillic acid, methyl esters of dihydroperillic acid, limonene-2-diol, uroterpenol, and combinations thereof.
- Formulation of the CoQ-10 can be accomplished by many methods known in the art.
- the solubilized CoQ-10 can be formulated in a suspension, an emulsion, an elixir, a solution, a caplet that harbors the liquid, or in a soft gelatin capsule.
- the formulation will include an acceptable carrier, such as an oil, or other suspending agent.
- Suitable carriers include but are not limited to, for example, fatty acids, esters and salts thereof, that can be derived from any source, including, without limitation, natural or synthetic oils, fats, waxes or combinations thereof. Moreover, the fatty acids can be derived, without limitation, from non-hydrogenated oils, partially hydrogenated oils, fully hydrogenated oils or combinations thereof.
- Non-limiting exemplary sources of fatty acids include seed oil, fish or marine oil, canola oil, vegetable oil, safflower oil, sunflower oil, nasturtium seed oil, mustard seed oil, olive oil, sesame oil, soybean oil, corn oil, peanut oil, cottonseed oil, rice bran oil, babassu nut oil, palm oil, low erucic rapeseed oil, palm kernel oil, lupin oil, coconut oil, flaxseed oil, evening primrose oil, jojoba, tallow, beef tallow, butter, chicken fat, lard, dairy butterfat, shea butter or combinations thereof.
- fish or marine oil sources include shellfish oil, tuna oil, mackerel oil, salmon oil, menhaden, anchovy, herring, trout, sardines or combinations thereof.
- the source of the fatty acids is fish or marine oil (DHA or EPA), soybean oil or flaxseed oil.
- beeswax can be used as a suitable carrier, as well as suspending agents such as silica (silicon dioxide).
- the formulations of the invention are considered dietary supplements useful to the increase the amounts of CoQ-10 in the individuals in need thereof.
- formulations of the invention are also considered to be nutraceuticals.
- the term “nutraceutical” is recognized in the art and is intended to describe specific chemical compounds found in foods that may prevent disease. CoQ-10 is one such compound.
- the formulations of the invention can further include various ingredients to help stabilize, or help promote the bioavailability of the CoQ-10, or serve as additional nutrients to an individual's diet.
- Suitable additives can include vitamins and biologically-acceptable minerals.
- vitamins include vitamin A, B vitamins, vitamin C, vitamin D, vitamin E, vitamin K and folic acid.
- minerals include iron, calcium, magnesium, potassium, copper, chromium, zinc, molybdenum, iodine, boron, selenium, manganese, derivatives thereof or combinations thereof. These vitamins and minerals may be from any source or combination of sources, without limitation.
- Non-limiting exemplary B vitamins include, without limitation, thiamine, niacinamide, pyridoxine, riboflavin, cyanocobalamin, biotin, pantothenic acid or combinations thereof.
- Vitamin(s), if present, are present in the composition of the invention in an amount ranging from about 5 mg to about 500 mg. More particularly, the vitamin(s) is present in an amount ranging from about 10 mg to about 400 mg. Even more specifically, the vitamin(s) is present from about 250 mg to about 400 mg. Most specifically, the vitamin(s) is present in an amount ranging from about 10 mg to about 50 mg.
- B vitamins are in usually incorporated in the range of about 1 milligram to about 10 milligrams, i.e., from about 3 micrograms to about 50 micrograms of B12.
- Folic acid for example, is generally incorporated in a range of about 50 to about 400 micrograms, biotin is generally incorporated in a range of about 25 to about 700 micrograms and cyanocobalamin is incorporated in a range of about 3 micrograms to about 50 micrograms.
- Mineral(s), if present, are present in the composition of the invention in an amount ranging from about 25 mg to about 1000 mg. More particularly, the mineral(s) are present in the composition ranging from about 25 mg to about 500 mg. Even more particularly, the mineral(s) are present in the composition in an amount ranging from about 100 mg to about 600 mg.
- additives can be incorporated into the present compositions.
- Optional additives of the present composition include, without limitation, phospholipids, L-carnitine, starches, sugars, fats, antioxidants, amino acids, proteins, flavorings, coloring agents, hydrolyzed starch(es) and derivatives thereof or combinations thereof.
- phospholipid is recognized in the art, and refers to phosphatidyl glycerol, phosphatidyl inositol, phosphatidyl serine, phosphatidyl choline, phosphatidyl ethanolamine, as well as phosphatidic acids, ceramides, cerebrosides, sphingomyelins and cardiolipins.
- L-carnitine is recognized in the art and facilitates transport of materials through the mitochondrial membrane.
- L-carnitine is an essential fatty acid metabolism cofactor that helps to move fatty acids to the mitochondria from the cytoplasm. This is an important factor as this is where CoQ-10 uptake occurs.
- L-carnitine is included in soft gel formulations in combination with CoQ-10.
- Suitable ratios of L-carnitine and CoQ-10 are known in the art and include those described in U.S. Pat. No. 4,599,232, issued to Sigma Tau Industrie Faramaceutiche Riunite S.p.A. on Jul. 8, 1986, the teachings of which are incorporated herein in their entirety.
- combinations of limonene, CoQ-10 and L-carnitine in soft gel formulations are of importance.
- the present invention provides the advantage of solvating large amounts (relative to that of current state of the art) of CoQ-10 in limonene in a soft gel capsule along with an additive, such as L-carnitine.
- antioxidant refers to synthetic or natural substances that prevent or delay the oxidative deterioration of a compound.
- exemplary antioxidants include tocopherols, flavonoids, catechins, superoxide dismutase, lecithin, gamma oryzanol; vitamins, such as vitamins A, C (ascorbic acid) and E and beta-carotene; natural components such as camosol, carnosic acid and rosmanol found in rosemary and hawthorn extract, proanthocyanidins such as those found in grapeseed or pine bark extract, and green tea extract.
- flavonoid as used herein is recognized in the art and is intended to include those plant pigments found in many foods that are thought to help protect the body from cancer. These include, for example, epi-gallo catechin gallate (EGCG), epi-gallo catechin (EGC) and epi-catechin (EC).
- EGCG epi-gallo catechin gallate
- ECC epi-gallo catechin
- EC epi-catechin
- any dosage form, and combinations thereof, are contemplated by the present invention.
- dosage forms include, without limitation, chewable tablets, elixirs, liquids, solutions, suspensions, emulsions, capsules, soft gelatin capsules, hard gelatin capsules, caplets, lozenges, chewable lozenges, suppositories, creams, topicals, ingestibles, injectables, infusions, health bars, confections, animal feeds, cereals, cereal coatings, and combinations thereof.
- the preparation of the above dosage forms are well known to persons of ordinary skill in the art.
- health bars can be prepared, without limitation, by mixing the formulation plus excipients (e.g., binders, fillers, flavors, colors, etc.) to a plastic mass consistency. The mass is then either extended or molded to form “candy bar” shapes that are then dried or allowed to solidify to form the final product.
- excipients e.g., binders, fillers, flavors, colors, etc.
- Soft gel or soft gelatin capsules can be prepared, for example, without limitation, by dispersing the formulation in an appropriate vehicle (e.g. rice bran oil, monoterpene and/or beeswax) to form a high viscosity mixture. This mixture is then encapsulated with a gelatin based film using technology and machinery known to those in the soft gel industry. The industrial units so formed are then dried to constant weight. Typically, the weight of the capsule is between about 100 to about 2500 milligrams and in particular weigh between about 1500 and about 1900 milligrams, and more specifically can weigh between about 1500 and about 2000 milligrams.
- an appropriate vehicle e.g. rice bran oil, monoterpene and/or beeswax
- This mixture is then encapsulated with a gelatin based film using technology and machinery known to those in the soft gel industry.
- the industrial units so formed are then dried to constant weight.
- the weight of the capsule is between about 100 to about 2500 milligrams and in particular weigh between about 1500
- the shell when preparing soft gelatin shells, can include between about 20 to 70 percent gelatin, generally a plasticizer and about 5 to about 60% by weight sorbitol.
- the filling of the soft gelatin capsule is liquid (principally limonene, in combination with rice bran oil and/or beeswax if desired) and can include, apart form the antioxidant actives, a hydrophilic matrix.
- the hydrophilic matrix is a polyethylene glycol having an average molecular weight of from about 200 to 1000. Further ingredients are optionally thickening agents.
- the hydrophilic matrix includes polyethylene glycol having an average molecular weight of from about 200 to 1000, 5 to 15% glycerol, and 5 to 15% by weight of water.
- the polyethylene glycol can also be mixed with propylene glycol and/or propylene carbonate.
- the soft gel capsule is prepared from gelatin, glycerine, water and various additives.
- the percentage (by weight) of the gelatin is between about 30 and about 50 weight percent, in particular between about 35 and about weight percent and more specifically about 42 weight percent.
- the formulation includes between about 15 and about 25 weight percent glycerine, more particularly between about 17 and about 23 weight percent and more specifically about 20 weight percent glycerine.
- the remaining portion of the capsule is typically water.
- the amount varies from between about 25 weigh percent and about 40 weight percent, more particularly between about 30 and about 35 weight percent, and more specifically about 35 weight percent.
- the remainder of the capsule can vary, generally, between about 2 and about 10 weight percent composed of a flavoring agent(s), sugar, coloring agent(s), etc. or combination thereof
- the water content of the final capsule is often between about 5 and about 10 weight percent, more particularly 7 and about 12 weight percent, and more specifically between about 9 and about 10 weight percent.
- soft shell gelatin capsule manufacturing techniques can be used to prepare the soft-shell product.
- useful manufacturing techniques are the plate process, the rotary die process pioneered by R. P. Scherer, the process using the Norton capsule machine, and the Accogel machine and process developed by Lederle. Each of these processes are mature technologies and are all widely available to any one wishing to prepare soft gelatin capsules.
- the total weight is between about 250 milligrams and about 2.5 gram in weight, e.g., 400-750 milligrams. Therefore, the total weight of additives, such as vitamins and antioxidants, is between about 80 milligrams and about 2000 milligrams, alternatively, between about 100 milligrams and about 1500 milligrams, and in particular between about 120 milligrams and about 1200 milligrams.
- additives such as vitamins and antioxidants
- a soft gel capsule can be prepared by mixing a 35% solution of CoQ-10 and limonene (w/w) (e.g., 104 milligrams of CoQ-10 in 193.14 milligrams of limonene) with between about 0.01 grams and about 0.4 grams (e.g., 0.1 grams) tocopherol, between about 200 grams and about 250 grams (e.g., 225 grams) rice bran oil and between about 0.01 grams and about 0.5 grams betacarotene (e.g. about 0.02 grams). The mixture is then combined with encapsulated within a gelatin capsule as described above.
- limonene w/w
- tocopherol between about 200 grams and about 250 grams (e.g., 225 grams) rice bran oil
- betacarotene e.g. about 0.02 grams
- the present invention also provides packaged formulations of a monoterpene with CoQ-10 and instructions for use of the tablet, capsule, elixir, etc.
- the packaged formulation in whatever form, is administered to an individual in need thereof that requires and increase in the amount of CoQ-10 in the individual's diet.
- the dosage requirements is between about 1 to about 4 dosages a day.
- CoQ-10 has been implicated in various biochemical pathways and is suitable for the treatment of cardiovascular conditions, such as those associated with, for example, statin drugs that effect the body's ability to product coQ-10 naturally. CoQ-10 has also been implicated in various periodontal diseases. Furthermore, CoQ-10 has been implicated in mitochondrial related diseases and disorders, such as the inability to product acetyl coenzyme A, neurological disorders, for example, such as Parkinson's disease and, Prater-Willey syndrome.
- Formulations of CoQ-10 can be prepared in the following ratios by mixing the components together and then placing into a soft gel capsule.
- Example 2 CoQ-10 104.09 mg 104.09 mg Mixed Tocopherols 269.03 mg 269.03 mg (372 IU/g) Rice Bran Oil 176.02 mg — Natural Beta Carotene 10.05 mg 10.05 mg (20% by weight) Yellow Beeswax 20.0 mg — D-limonene — 196.02 mg Total weight 580 mg 580 mg
- Example 2 demonstrates that the use of limonene solubilizes CoQ-10 without the requirement of beeswax and/or rice bran oil being present. Examples 1 and 2 could be incorporated into soft gel capsules by standard methods known in the art.
- Example 4 CoQ-10 17.95 g 17.95 g EPAX 2050TG 48.77 g 45.49 g D-Limonene 35.70 g 35.70 g 5-67 Tocopherol — 0.86 g (1000 IU/g)
- Examples 3 and 4 demonstrate that CoQ-10 can be solubilized in scalable quantities.
- Additives such as EPAX 2050 TG (an ⁇ -3 oil; 20% EPA/50% DHA as triglycerides, remainder fatty acid/triglycerides; Pronova Biocare) and tocopherols (5-67 Tocopherol; BD Industries) can easily be incorporated into such limonene containing formulations.
- the resultant mixtures contained approximately 100 mg of CoQ-10 per soft gel capsule. Preparation of the soft gel capsules was accomplished by methods well known in the art.
Abstract
The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.
Description
- None.
- The present invention relates to the solubilization of coenzyme Q-10 and analogs thereof in monoterpenes, thereby providing increased bioavailability in delivery.
- CoQ-10 (coenzyme Q10) is a fat-soluble quinone that is structurally similar to vitamin K and commonly known as ubiquinone. CoQ-10 is found in most living organisms, and is essential for the production of cellular energy. CoQ-10 (2,3 dimethyl-5 methyl-6-decaprenyl benzoquinone) is an endogenous antioxidant found in small amounts in meats and seafood. Although CoQ-10 is found in all human cells, the highest concentrations of CoQ-10 occur in the heart, liver, kidneys, and pancreas. It is found naturally in the organs of many mammalian species.
- CoQ-10 can be synthesized in the body or it can be derived from dietary sources. Situations may arise, however, when the need for CoQ-10 surpasses the body's ability to synthesize it. CoQ-10 can be absorbed by oral supplementation as evidenced by significant increases in serum CoQ-10 levels after supplementation.
- CoQ-10 is an important nutrient because it lies within the membrane of a cell organelle called the mitochondria. Mitochondria are known as the “power house” of the cell because of their ability to produce cellular energy, or ATP, by shuttling protons derived from nutrient breakdown through the process of aerobic (oxygen) metabolism. CoQ-10 also has a secondary role as an antioxidant. CoQ-10, due to the involvement in ATP synthesis, affects the function of almost all cells in the body, making it essential for the health of all human tissues and organs. CoQ-10 particularly effects the cells that are the most metabolically active: heart, immune system, gingiva, and gastric mucosa
- Several clinical trials have shown CoQ-10 to be effective in supporting blood pressure and cholesterol levels. Furthermore, CoQ-10 has also been shown to improve cardiovascular health. CoQ-10 has been implicated as being an essential component in thwarting various diseases such as certain types of cancers. These facts lead many to believe that CoQ-10 supplementation is vital to an individual's well being.
- CoQ-10 is sparingly soluble in most hydrophilic solvents such as water. Therefore, CoQ-10 is often administered in a powdered form, as in a tablet or as a suspension. However, delivery of CoQ-10 by these methods limits the bioavailability of the material to the individual.
- There is a need in the art for an improved methodology to deliver increased amount of bioavailable CoQ-10 to an individual in need thereof.
- The present invention pertains to the surprising discovery that ubiquinone (CoQ-10) can be readily dissolved in varying concentrations in monoterpenes. Generally, until the present discovery, most CoQ-10 liquid delivery methods could solubilize only up to about 5% by weight of the CoQ-10 in the “solvent”. Typical solvents included various oils or the CoQ-10 was held in suspension. The present invention provides the ability to solubilize CoQ-10 in monoterpenes in concentrations of up to about 60% (weight to weight) without the need to aggressively heat the solution or with gentle warming. In particular, the solubilization of the CoQ-10 with monoterpenes can be accomplished at ambient temperatures.
- In one aspect, the present invention pertains to compositions that include coenzyme Q-10 or an analog thereof with a sufficient quantity of a monoterpene that is suitable to solubilize said coenzyme Q-10 and a pharmaceutically acceptable carrier. Generally, about 30 to about 45% of the CoQ-10 (by weight) is solubilized in the monoterpene. In particular, the monoterpene is limonene. The compositions of the invention are useful as dietary supplements or as nutriceuticals.
- In particular, the compositions of the invention are included in a soft gelatin (soft gel) capsule. Typically, the soft gelatin capsule includes at least 5% by weight of coenzyme Q-10 or an analog thereof solubilized in a monoterpene. Typical monoterpenes include, for example, perillyl alcohol, perillic acid, cis-dihydroperillic acid, trans-dihydroperillic acid, methyl esters of perillic acid, methyl esters of dihydroperillic acid, limonene-2-diol, uroterpenol, and combinations thereof.
- In another embodiment, the present invention pertains to methods for delivery of an effective amount of bioavailable CoQ-10 to an individual. The method includes providing CoQ-10 solubilized in a monoterpene, such that an effective amount of CoQ-10 is provided to the individual.
- In still another embodiment, the present invention also includes packaged formulations of the invention that include a monoterpene as a solvent for the CoQ-10 and instructions for use of the tablet, capsule, elixir, etc.
- While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. As will be realized, the invention is capable of modifications in various obvious aspects, all without departing from the spirit and scope of the present invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.
- The present invention pertains to the surprising discovery that ubiquinone (CoQ-10) can be readily dissolved in varying concentrations in monoterpenes. CoQ-10 is found in most living organisms, and is essential for the production of cellular energy. Ubiquinone is a naturally occurring hydrogen carrier in the respiratory chain (coenzyme Q) and structurally, it is a 2,3-dimethoxy-5-methyl-1,4-benzoquinone with a multiprenyl side chain, the number of isoprene units varying depending upon the organism from which it is derived. CoQ-10 analogs include reduced and semi-reduced CoQ-10 and ubiquinone derivatives described, for example, in WO 8803015, the teachings of which are incorporated herein by reference.
- Generally, until the present discovery, most CoQ-10 liquid delivery methods could solubilize only up at most about 10% by weight of the CoQ-10 in the “solvent. Typical solvents included oils or the CoQ-10 was held in an aqueous suspension. Alternatively, the CoQ-10 was provided as a solid in a tablet or powder.
- The present invention provides the ability to solubilize CoQ-10 in monoterpenes, as defined herein, in concentrations of up to about 60% (weight to weight) without the need to heat the solution. In one aspect, the monoterpene solubilizes CoQ-10 from about 0.1 percent by weight to about 45 percent by weight.
- In particular, the solubilization of the CoQ-10 with monoterpenes can be accomplished at ambient temperatures. In one aspect, from about 5 to about 50 percent (weight CoQ-10/weight solvent) CoQ-10 can be solubilized in a monoterpene. In another aspect, from about 15 to about 40 percent w/w can be solubilized and in still another aspect, from about 20 to about 35 percent w/w CoQ-10 can be solubilized in a monoterpene.
- The phrase “sufficient quantity of a monoterpene suitable to solubilize coenzyme Q-10” is therefore intended to mean that that amount of a monoterpene that will dissolve CoQ-10 under a given set of conditions, generally, those at ambient temperature. This determination should be understood by one skilled in the art and can be determined by methods known in the art, such as by solubility studies.
- One of the particular advantages of utilizing monoterpenes in combination with CoQ-10 is that the enzyme is dissolved by the monoterpene. That is, many formulations currently in the marketplace have CoQ-10 present as a suspension; a situation where not all the CoQ-10 is dissolved. This reduces efficacy and the bioavailability of the CoQ-10. The present invention eliminates this disadvantage by solubilizing the CoQ-10 in the monoterpene.
- A particular advantage in using monoterpenes is that the CoQ-10 does not have to be heated to dissolve into solution. This is important so that the CoQ-10 does not degrade upon dissolution.
- The term “monoterpene” as used herein, refers to a compound having a 10-carbon skeleton with non-linear branches. A monoterpene refers to a compound with two isoprene units connected in a head-to-end manner. The term “monoterpene” is also intended to include “monoterpenoid”, which refers to a monoterpene-like substance and may be used loosely herein to refer collectively to monoterpenoid derivatives as well as monoterpenoid analogs. Monoterpenoids can therefore include monoterpenes, alcohols, ketones, aldehydes, ethers, acids, hydrocarbons without an oxygen functional group, and so forth.
- It is common practice to refer to certain phenolic compounds, such as eugenol, thymol and carvacrol, as monoterpenoids because their function is essentially the same as a monoterpenoid. However, these compounds are not technically “monoterpenoids” (or “monoterpenes”) because they are not synthesized by the same isoprene biosynthesis pathway, but rather by production of phenols from tyrosine. However, common practice will be followed herein. Suitable examples of monoterpenes include, but are not limited to, limonene, pinene, cintronellol, terpinene, nerol, menthane, carveol, S-linalool, safrol, cinnamic acid, apiol, geraniol, thymol, citral, carvone, camphor, etc. and derivatives thereof. For information about the structure and synthesis of terpenes, including terpenes of the invention, see Kirk-Othmer Encyclopedia of Chemical Technology, Mark, et al., eds., 22:709-762 3d Ed (1983), the teachings of which are incorporated herein in their entirety.
- In particular, suitable limonene derivatives include perillyl alcohol, perillic acid, cis-dihydroperillic acid, trans-dihydroperillic acid, methyl esters of perillic acid, methyl esters of dihydroperillic acid, limonene-2-diol, uroterpenol, and combinations thereof.
- Formulation of the CoQ-10 can be accomplished by many methods known in the art. For example, the solubilized CoQ-10 can be formulated in a suspension, an emulsion, an elixir, a solution, a caplet that harbors the liquid, or in a soft gelatin capsule. Often the formulation will include an acceptable carrier, such as an oil, or other suspending agent.
- Suitable carriers include but are not limited to, for example, fatty acids, esters and salts thereof, that can be derived from any source, including, without limitation, natural or synthetic oils, fats, waxes or combinations thereof. Moreover, the fatty acids can be derived, without limitation, from non-hydrogenated oils, partially hydrogenated oils, fully hydrogenated oils or combinations thereof. Non-limiting exemplary sources of fatty acids (their esters and salts) include seed oil, fish or marine oil, canola oil, vegetable oil, safflower oil, sunflower oil, nasturtium seed oil, mustard seed oil, olive oil, sesame oil, soybean oil, corn oil, peanut oil, cottonseed oil, rice bran oil, babassu nut oil, palm oil, low erucic rapeseed oil, palm kernel oil, lupin oil, coconut oil, flaxseed oil, evening primrose oil, jojoba, tallow, beef tallow, butter, chicken fat, lard, dairy butterfat, shea butter or combinations thereof.
- Specific non-limiting exemplary fish or marine oil sources include shellfish oil, tuna oil, mackerel oil, salmon oil, menhaden, anchovy, herring, trout, sardines or combinations thereof. In particular, the source of the fatty acids is fish or marine oil (DHA or EPA), soybean oil or flaxseed oil. Alternatively or in combination with one of the above identified carrier, beeswax can be used as a suitable carrier, as well as suspending agents such as silica (silicon dioxide).
- The formulations of the invention are considered dietary supplements useful to the increase the amounts of CoQ-10 in the individuals in need thereof.
- Alternatively, the formulations of the invention are also considered to be nutraceuticals. The term “nutraceutical” is recognized in the art and is intended to describe specific chemical compounds found in foods that may prevent disease. CoQ-10 is one such compound.
- The formulations of the invention can further include various ingredients to help stabilize, or help promote the bioavailability of the CoQ-10, or serve as additional nutrients to an individual's diet. Suitable additives can include vitamins and biologically-acceptable minerals. Non-limiting examples of vitamins include vitamin A, B vitamins, vitamin C, vitamin D, vitamin E, vitamin K and folic acid. Non-limiting examples of minerals include iron, calcium, magnesium, potassium, copper, chromium, zinc, molybdenum, iodine, boron, selenium, manganese, derivatives thereof or combinations thereof. These vitamins and minerals may be from any source or combination of sources, without limitation. Non-limiting exemplary B vitamins include, without limitation, thiamine, niacinamide, pyridoxine, riboflavin, cyanocobalamin, biotin, pantothenic acid or combinations thereof.
- Vitamin(s), if present, are present in the composition of the invention in an amount ranging from about 5 mg to about 500 mg. More particularly, the vitamin(s) is present in an amount ranging from about 10 mg to about 400 mg. Even more specifically, the vitamin(s) is present from about 250 mg to about 400 mg. Most specifically, the vitamin(s) is present in an amount ranging from about 10 mg to about 50 mg. For example, B vitamins are in usually incorporated in the range of about 1 milligram to about 10 milligrams, i.e., from about 3 micrograms to about 50 micrograms of B12. Folic acid, for example, is generally incorporated in a range of about 50 to about 400 micrograms, biotin is generally incorporated in a range of about 25 to about 700 micrograms and cyanocobalamin is incorporated in a range of about 3 micrograms to about 50 micrograms.
- Mineral(s), if present, are present in the composition of the invention in an amount ranging from about 25 mg to about 1000 mg. More particularly, the mineral(s) are present in the composition ranging from about 25 mg to about 500 mg. Even more particularly, the mineral(s) are present in the composition in an amount ranging from about 100 mg to about 600 mg.
- Various additives can be incorporated into the present compositions. Optional additives of the present composition include, without limitation, phospholipids, L-carnitine, starches, sugars, fats, antioxidants, amino acids, proteins, flavorings, coloring agents, hydrolyzed starch(es) and derivatives thereof or combinations thereof.
- As used herein, the term “phospholipid” is recognized in the art, and refers to phosphatidyl glycerol, phosphatidyl inositol, phosphatidyl serine, phosphatidyl choline, phosphatidyl ethanolamine, as well as phosphatidic acids, ceramides, cerebrosides, sphingomyelins and cardiolipins.
- L-carnitine is recognized in the art and facilitates transport of materials through the mitochondrial membrane. L-carnitine is an essential fatty acid metabolism cofactor that helps to move fatty acids to the mitochondria from the cytoplasm. This is an important factor as this is where CoQ-10 uptake occurs.
- In one aspect of the present invention, L-carnitine is included in soft gel formulations in combination with CoQ-10. Suitable ratios of L-carnitine and CoQ-10 are known in the art and include those described in U.S. Pat. No. 4,599,232, issued to Sigma Tau Industrie Faramaceutiche Riunite S.p.A. on Jul. 8, 1986, the teachings of which are incorporated herein in their entirety. In particular, combinations of limonene, CoQ-10 and L-carnitine in soft gel formulations are of importance. The present invention provides the advantage of solvating large amounts (relative to that of current state of the art) of CoQ-10 in limonene in a soft gel capsule along with an additive, such as L-carnitine.
- As used herein, the term “antioxidant” is recognized in the art and refers to synthetic or natural substances that prevent or delay the oxidative deterioration of a compound. Exemplary antioxidants include tocopherols, flavonoids, catechins, superoxide dismutase, lecithin, gamma oryzanol; vitamins, such as vitamins A, C (ascorbic acid) and E and beta-carotene; natural components such as camosol, carnosic acid and rosmanol found in rosemary and hawthorn extract, proanthocyanidins such as those found in grapeseed or pine bark extract, and green tea extract.
- The term “flavonoid” as used herein is recognized in the art and is intended to include those plant pigments found in many foods that are thought to help protect the body from cancer. These include, for example, epi-gallo catechin gallate (EGCG), epi-gallo catechin (EGC) and epi-catechin (EC).
- Any dosage form, and combinations thereof, are contemplated by the present invention. Examples of such dosage forms include, without limitation, chewable tablets, elixirs, liquids, solutions, suspensions, emulsions, capsules, soft gelatin capsules, hard gelatin capsules, caplets, lozenges, chewable lozenges, suppositories, creams, topicals, ingestibles, injectables, infusions, health bars, confections, animal feeds, cereals, cereal coatings, and combinations thereof. The preparation of the above dosage forms are well known to persons of ordinary skill in the art.
- For example, health bars can be prepared, without limitation, by mixing the formulation plus excipients (e.g., binders, fillers, flavors, colors, etc.) to a plastic mass consistency. The mass is then either extended or molded to form “candy bar” shapes that are then dried or allowed to solidify to form the final product.
- Soft gel or soft gelatin capsules can be prepared, for example, without limitation, by dispersing the formulation in an appropriate vehicle (e.g. rice bran oil, monoterpene and/or beeswax) to form a high viscosity mixture. This mixture is then encapsulated with a gelatin based film using technology and machinery known to those in the soft gel industry. The industrial units so formed are then dried to constant weight. Typically, the weight of the capsule is between about 100 to about 2500 milligrams and in particular weigh between about 1500 and about 1900 milligrams, and more specifically can weigh between about 1500 and about 2000 milligrams.
- For example, when preparing soft gelatin shells, the shell can include between about 20 to 70 percent gelatin, generally a plasticizer and about 5 to about 60% by weight sorbitol. The filling of the soft gelatin capsule is liquid (principally limonene, in combination with rice bran oil and/or beeswax if desired) and can include, apart form the antioxidant actives, a hydrophilic matrix.
- The hydrophilic matrix, if present, is a polyethylene glycol having an average molecular weight of from about 200 to 1000. Further ingredients are optionally thickening agents. In one embodiment, the hydrophilic matrix includes polyethylene glycol having an average molecular weight of from about 200 to 1000, 5 to 15% glycerol, and 5 to 15% by weight of water. The polyethylene glycol can also be mixed with propylene glycol and/or propylene carbonate.
- In another embodiment, the soft gel capsule is prepared from gelatin, glycerine, water and various additives. Typically, the percentage (by weight) of the gelatin is between about 30 and about 50 weight percent, in particular between about 35 and about weight percent and more specifically about 42 weight percent. The formulation includes between about 15 and about 25 weight percent glycerine, more particularly between about 17 and about 23 weight percent and more specifically about 20 weight percent glycerine.
- The remaining portion of the capsule is typically water. The amount varies from between about 25 weigh percent and about 40 weight percent, more particularly between about 30 and about 35 weight percent, and more specifically about 35 weight percent. The remainder of the capsule can vary, generally, between about 2 and about 10 weight percent composed of a flavoring agent(s), sugar, coloring agent(s), etc. or combination thereof After the capsule is processed, the water content of the final capsule is often between about 5 and about 10 weight percent, more particularly 7 and about 12 weight percent, and more specifically between about 9 and about 10 weight percent.
- As for the manufacturing, it is contemplated that standard soft shell gelatin capsule manufacturing techniques can be used to prepare the soft-shell product. Examples of useful manufacturing techniques are the plate process, the rotary die process pioneered by R. P. Scherer, the process using the Norton capsule machine, and the Accogel machine and process developed by Lederle. Each of these processes are mature technologies and are all widely available to any one wishing to prepare soft gelatin capsules.
- Typically, when a soft gel capsule is prepared, the total weight is between about 250 milligrams and about 2.5 gram in weight, e.g., 400-750 milligrams. Therefore, the total weight of additives, such as vitamins and antioxidants, is between about 80 milligrams and about 2000 milligrams, alternatively, between about 100 milligrams and about 1500 milligrams, and in particular between about 120 milligrams and about 1200 milligrams.
- For example, a soft gel capsule can be prepared by mixing a 35% solution of CoQ-10 and limonene (w/w) (e.g., 104 milligrams of CoQ-10 in 193.14 milligrams of limonene) with between about 0.01 grams and about 0.4 grams (e.g., 0.1 grams) tocopherol, between about 200 grams and about 250 grams (e.g., 225 grams) rice bran oil and between about 0.01 grams and about 0.5 grams betacarotene (e.g. about 0.02 grams). The mixture is then combined with encapsulated within a gelatin capsule as described above.
- The present invention also provides packaged formulations of a monoterpene with CoQ-10 and instructions for use of the tablet, capsule, elixir, etc. Typically, the packaged formulation, in whatever form, is administered to an individual in need thereof that requires and increase in the amount of CoQ-10 in the individual's diet. Typically, the dosage requirements is between about 1 to about 4 dosages a day.
- CoQ-10 has been implicated in various biochemical pathways and is suitable for the treatment of cardiovascular conditions, such as those associated with, for example, statin drugs that effect the body's ability to product coQ-10 naturally. CoQ-10 has also been implicated in various periodontal diseases. Furthermore, CoQ-10 has been implicated in mitochondrial related diseases and disorders, such as the inability to product acetyl coenzyme A, neurological disorders, for example, such as Parkinson's disease and, Prater-Willey syndrome.
- The following examples are intended to be illustrative only and should not be considered limiting.
- Formulations of CoQ-10 can be prepared in the following ratios by mixing the components together and then placing into a soft gel capsule.
-
Component Example 1 Example 2 CoQ-10 104.09 mg 104.09 mg Mixed Tocopherols 269.03 mg 269.03 mg (372 IU/g) Rice Bran Oil 176.02 mg — Natural Beta Carotene 10.05 mg 10.05 mg (20% by weight) Yellow Beeswax 20.0 mg — D-limonene — 196.02 mg Total weight 580 mg 580 mg - Example 2 demonstrates that the use of limonene solubilizes CoQ-10 without the requirement of beeswax and/or rice bran oil being present. Examples 1 and 2 could be incorporated into soft gel capsules by standard methods known in the art.
-
Component Example 3 Example 4 CoQ-10 17.95 g 17.95 g EPAX 2050TG 48.77 g 45.49 g D-Limonene 35.70 g 35.70 g 5-67 Tocopherol — 0.86 g (1000 IU/g) - Examples 3 and 4 demonstrate that CoQ-10 can be solubilized in scalable quantities. Additives, such as EPAX 2050 TG (an ω-3 oil; 20% EPA/50% DHA as triglycerides, remainder fatty acid/triglycerides; Pronova Biocare) and tocopherols (5-67 Tocopherol; BD Industries) can easily be incorporated into such limonene containing formulations. The resultant mixtures contained approximately 100 mg of CoQ-10 per soft gel capsule. Preparation of the soft gel capsules was accomplished by methods well known in the art.
- Although the present invention has been described with reference to preferred embodiments, persons skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention.
- All literature and patent references cited throughout the application are incorporated by reference into the application for all purposes.
Claims (21)
1. A composition comprising:
coenzyme Q-10 or an analog thereof;
a sufficient quantity of a monoterpene suitable to solubilize said coenzyme Q-10; and
an acceptable carrier.
2. The composition of claim 1 , wherein said coenzyme Q-10 or an analog thereof is selected from the group consisting of coenzyme Q-10, reduced coenzyme Q-10 and semi-reduced coenzyme Q-10.
3. The composition of claim 1 , wherein said monoterpene is limonene or a derivative thereof.
4. The composition of claim 3 , wherein said limonene derivatives are selected from the group consisting of perillyl alcohol, perillic acid, cis-dihydroperillic acid, trans-dihydroperillic acid, methyl esters of perillic acid, methyl esters of dihydroperillic acid, limonene-2-diol, uroterpenol, and combinations thereof.
5. The composition of claim 1 , wherein said composition is in the form of a solution, an elixir, a suspension, or a caplet.
6. The composition of claim 5 , wherein said caplet is a soft gelatin tablet.
7. The composition of claim 6 , wherein said soft gelatin tablet further comprises rice bran oil or beeswax.
8. The composition of claim 1 , wherein said coenzyme Q-10 or analog thereof is solubilized in said monoterpene in an amount of at least about 0.1% by weight to about 45% by weight at room temperature.
9. The composition of claim 1 , wherein said coenzyme Q-10 or analog thereof is solubilized in said monoterpene in an amount of least about 5% to about 40% by weight at room temperature.
10. The composition of claim 1 , further comprising vitamin E.
11. The composition of claim 1 , further comprising a seed oil.
12. The composition of claim 1 , further comprising a fish oil
13. The composition of claim 1 , further comprising an antioxidant.
14. A soft gelatin capsule, comprising
at least 5% by weight of coenzyme Q-10 or an analog thereof solubilized in a monoterpene.
15. The soft gelatin capsule of claim 14 , wherein said coenzyme Q-10 or analog thereof is selected from the group consisting of coenzyme Q-10, reduced coenzyme Q-10 and semi-reduced coenzyme Q-10.
16. The soft gelatin capsule of claim 14 , wherein said monoterpene is limonene or a derivative thereof.
17. The soft gelatin capsule of claim 16 , wherein said limonene derivative is selected from the group consisting of perillyl alcohol, perillic acid, cis-dihydroperillic acid, trans-dihydroperillic acid, methyl esters of perillic acid, methyl esters of dihydroperillic acid, limonene-2-diol, uroterpenol, and combinations thereof.
18. The soft gelatin capsule of claim 14 , wherein said coenzyme Q-10 is solubilized in said monoterpene in an amount of about 10 percent to about 40 percent by weight.
19. The composition of claim 14 , wherein said soft gelatin tablet further comprises rice bran oil or beeswax.
20. The composition of claim 14 , wherein said soft gelatin tablet further comprises an antioxidant.
21-24. (canceled)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/565,679 US20150216807A1 (en) | 2003-09-29 | 2014-12-10 | Solubilized coq-10 |
US15/229,750 US10166192B2 (en) | 2003-09-29 | 2016-08-05 | Solubilized CoQ-10 |
US16/196,644 US20190192443A1 (en) | 2003-09-29 | 2018-11-20 | Solubilized coq-10 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/674,268 US8124072B2 (en) | 2003-09-29 | 2003-09-29 | Solubilized CoQ-10 |
US13/365,244 US8617541B2 (en) | 2003-09-29 | 2012-02-02 | Solubilized CoQ-10 |
US14/141,968 US8932584B2 (en) | 2003-09-29 | 2013-12-27 | Solubilized CoQ-10 |
US14/565,679 US20150216807A1 (en) | 2003-09-29 | 2014-12-10 | Solubilized coq-10 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/141,968 Continuation US8932584B2 (en) | 2003-09-29 | 2013-12-27 | Solubilized CoQ-10 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/229,750 Continuation US10166192B2 (en) | 2003-09-29 | 2016-08-05 | Solubilized CoQ-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
US20150216807A1 true US20150216807A1 (en) | 2015-08-06 |
Family
ID=34376843
Family Applications (13)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/674,268 Expired - Lifetime US8124072B2 (en) | 2003-09-29 | 2003-09-29 | Solubilized CoQ-10 |
US11/223,718 Expired - Lifetime US8147826B2 (en) | 2003-09-29 | 2005-09-09 | Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene |
US13/365,244 Expired - Lifetime US8617541B2 (en) | 2003-09-29 | 2012-02-02 | Solubilized CoQ-10 |
US13/406,794 Expired - Lifetime US8506859B2 (en) | 2003-09-29 | 2012-02-28 | Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene |
US13/966,063 Expired - Lifetime US8865032B2 (en) | 2003-09-29 | 2013-08-13 | Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene |
US14/141,968 Expired - Lifetime US8932584B2 (en) | 2003-09-29 | 2013-12-27 | Solubilized CoQ-10 |
US14/487,187 Abandoned US20150004304A1 (en) | 2003-09-29 | 2014-09-16 | SOLUBILIZED CoQ-10 |
US14/565,679 Abandoned US20150216807A1 (en) | 2003-09-29 | 2014-12-10 | Solubilized coq-10 |
US14/811,018 Abandoned US20160184238A1 (en) | 2003-09-29 | 2015-07-28 | SOLUBILIZED CoQ-10 |
US15/229,750 Expired - Lifetime US10166192B2 (en) | 2003-09-29 | 2016-08-05 | Solubilized CoQ-10 |
US15/359,912 Expired - Lifetime US10166193B2 (en) | 2003-09-29 | 2016-11-23 | Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene |
US16/196,644 Abandoned US20190192443A1 (en) | 2003-09-29 | 2018-11-20 | Solubilized coq-10 |
US16/196,296 Abandoned US20190091157A1 (en) | 2003-09-29 | 2018-11-20 | Method of Making a Soft Gel Capsule Comprising COQ-10 Solubilized in a Monoterpene |
Family Applications Before (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/674,268 Expired - Lifetime US8124072B2 (en) | 2003-09-29 | 2003-09-29 | Solubilized CoQ-10 |
US11/223,718 Expired - Lifetime US8147826B2 (en) | 2003-09-29 | 2005-09-09 | Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene |
US13/365,244 Expired - Lifetime US8617541B2 (en) | 2003-09-29 | 2012-02-02 | Solubilized CoQ-10 |
US13/406,794 Expired - Lifetime US8506859B2 (en) | 2003-09-29 | 2012-02-28 | Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene |
US13/966,063 Expired - Lifetime US8865032B2 (en) | 2003-09-29 | 2013-08-13 | Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene |
US14/141,968 Expired - Lifetime US8932584B2 (en) | 2003-09-29 | 2013-12-27 | Solubilized CoQ-10 |
US14/487,187 Abandoned US20150004304A1 (en) | 2003-09-29 | 2014-09-16 | SOLUBILIZED CoQ-10 |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/811,018 Abandoned US20160184238A1 (en) | 2003-09-29 | 2015-07-28 | SOLUBILIZED CoQ-10 |
US15/229,750 Expired - Lifetime US10166192B2 (en) | 2003-09-29 | 2016-08-05 | Solubilized CoQ-10 |
US15/359,912 Expired - Lifetime US10166193B2 (en) | 2003-09-29 | 2016-11-23 | Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene |
US16/196,644 Abandoned US20190192443A1 (en) | 2003-09-29 | 2018-11-20 | Solubilized coq-10 |
US16/196,296 Abandoned US20190091157A1 (en) | 2003-09-29 | 2018-11-20 | Method of Making a Soft Gel Capsule Comprising COQ-10 Solubilized in a Monoterpene |
Country Status (3)
Country | Link |
---|---|
US (13) | US8124072B2 (en) |
JP (1) | JP4758898B2 (en) |
IL (1) | IL174624A (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6616942B1 (en) * | 1999-03-29 | 2003-09-09 | Soft Gel Technologies, Inc. | Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing |
US20080089877A1 (en) * | 2003-08-14 | 2008-04-17 | Udell Ronald G | Super Absorption Coenzyme Q10 |
US8124072B2 (en) | 2003-09-29 | 2012-02-28 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
US8105583B2 (en) * | 2003-09-29 | 2012-01-31 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
US7169385B2 (en) * | 2003-09-29 | 2007-01-30 | Ronald G. Udell | Solubilized CoQ-10 and carnitine |
PL1718283T3 (en) | 2004-01-22 | 2013-08-30 | Univ Miami | Topical co-enzyme q10 formulations and methods of use |
US20060025475A1 (en) * | 2004-07-29 | 2006-02-02 | Stanley Antosh | Use of methyl pyruvate for the purpose of increasing muscle energy production. |
US8252326B2 (en) * | 2005-06-01 | 2012-08-28 | Catalent Australia Pty Ltd. | Self-microemulsifying dosage forms of low solubility active ingredients such as co-enzyme Q10 |
US20050249803A1 (en) * | 2005-06-03 | 2005-11-10 | Udell Ronald G | Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols |
US7887852B2 (en) * | 2005-06-03 | 2011-02-15 | Soft Gel Technologies, Inc. | Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols |
US20070184040A1 (en) * | 2006-02-06 | 2007-08-09 | Clouatre Dallas L | Compositions for delivery of coenzyme Q10 |
US8343541B2 (en) * | 2007-03-15 | 2013-01-01 | Soft Gel Technologies, Inc. | Ubiquinol and alpha lipoic acid compositions |
AU2008228764B2 (en) | 2007-03-22 | 2014-05-08 | Berg Llc | Topical formulations having enhanced bioavailability |
WO2009126764A1 (en) | 2008-04-11 | 2009-10-15 | Cytotech Labs, Llc | Methods and use of inducing apoptosis in cancer cells |
KR20180018833A (en) | 2009-05-11 | 2018-02-21 | 베르그 엘엘씨 | Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
AU2010276201B2 (en) * | 2009-07-21 | 2013-10-17 | Abt Holding Company | Use of stem cells to reduce leukocyte extravasation |
SG183508A1 (en) | 2010-03-12 | 2012-10-30 | Berg Pharma Llc | Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
JP5810079B2 (en) * | 2010-04-20 | 2015-11-11 | 株式会社カネカ | Reduced coenzyme Q10-containing composition, method for producing the same, and method for stabilizing the same |
SG10201503700WA (en) | 2010-05-12 | 2015-06-29 | Abt Holding Co | Modulation of splenocytes in cell therapy |
ES2762451T3 (en) | 2011-04-04 | 2020-05-25 | Berg Llc | Treatment of tumors of the central nervous system with coenzyme Q10 |
PE20140628A1 (en) | 2011-06-17 | 2014-05-30 | Berg Llc | INHALABLE PHARMACEUTICAL COMPOSITIONS |
BR112015025424A2 (en) | 2013-04-08 | 2017-07-18 | Berg Llc | cancer treatment using coenzyme q10 combination therapies |
JP6146129B2 (en) * | 2013-05-20 | 2017-06-14 | ユーハ味覚糖株式会社 | Method for producing reduced coenzyme Q10-containing gummy candy |
JP6398181B2 (en) * | 2013-11-29 | 2018-10-03 | ユーハ味覚糖株式会社 | Ubiquinol-rich gel composition |
US9757332B2 (en) | 2013-05-20 | 2017-09-12 | Uha Mikakuto Co., Ltd. | Gel-like composition having high ubiquinol content |
JP6459206B2 (en) * | 2014-04-25 | 2019-01-30 | ユーハ味覚糖株式会社 | Superabsorbent ubiquinol formulation |
AU2014315186B2 (en) | 2013-09-04 | 2020-02-27 | Berg Llc | Methods of treatment of cancer by continuous infusion of coenzyme Q10 |
WO2015071841A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
ES2545806B1 (en) * | 2014-03-12 | 2016-03-22 | Vitalgrana Pomegrante, Sl | Coenzyme Q10 and Omega 5 compound |
CN107568731B (en) * | 2017-10-19 | 2020-09-29 | 李宏 | Coenzyme Q10 fish oil nano emulsion and preparation method and application thereof |
CN109497564A (en) * | 2018-12-25 | 2019-03-22 | 杭州海王生物工程有限公司 | A kind of calcium soft capsule and preparation method thereof conveniently taken |
US11471426B2 (en) | 2019-10-16 | 2022-10-18 | American River Nutrition, Llc | Compositions comprising quinone and/or quinol and methods of preparations and use thereof |
Family Cites Families (138)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2263753B1 (en) | 1974-03-12 | 1978-07-21 | Roeck Yannick De | |
JPS5581813U (en) | 1978-11-29 | 1980-06-05 | ||
JPS5581813A (en) | 1978-12-16 | 1980-06-20 | Nisshin Flour Milling Co Ltd | Composition containing coenzyme q10 and its perparation |
IT1206954B (en) | 1979-02-12 | 1989-05-17 | Sigma Tau Ind Farmaceuti | THERAPEUTIC AGENTS BASED ON AN ACIL DERIVATIVE OF CARNITINE FOR THE TREATMENT OF PERIPHERAL VASCULOPATHIES |
JPS5671034A (en) | 1979-11-12 | 1981-06-13 | Japan Tobacco Inc | 4-keto-alpha-cyclocitral and improver of aroma and flavor of tobacco composed thereof |
JPS5742616A (en) * | 1980-08-27 | 1982-03-10 | Furointo Sangyo Kk | Ubiquinone pharmaceutical having improved absorption |
JPS5770815A (en) * | 1980-10-21 | 1982-05-01 | Furointo Sangyo Kk | Absorption improver |
JPS57142911A (en) | 1981-02-28 | 1982-09-03 | Furointo Sangyo Kk | Absorption-improving agent |
JPS6116815Y2 (en) | 1981-03-03 | 1986-05-23 | ||
JPS58180427A (en) | 1982-04-16 | 1983-10-21 | Tetsuya Suzuki | Preparation of substance having hypotensive component |
CH655005A5 (en) | 1983-02-16 | 1986-03-27 | Sigma Tau Ind Farmaceuti | PHARMACEUTICAL COMPOSITION WITH METABOLIC AND ENERGY ACTION USABLE IN CARDIAC AND VASCULAR THERAPY. |
JPS59172417A (en) | 1983-03-23 | 1984-09-29 | Nisshin Kagaku Kk | Soft capsule containing riboflavin butyrate |
US4559222A (en) | 1983-05-04 | 1985-12-17 | Alza Corporation | Matrix composition for transdermal therapeutic system |
JPS59172417U (en) | 1983-05-04 | 1984-11-17 | 北島 信男 | Water pillow that can be cooled by electricity |
JPS6025918A (en) | 1983-07-25 | 1985-02-08 | Ajinomoto Co Inc | Aqueous solution containing fat-soluble drug |
US4687782A (en) | 1984-12-10 | 1987-08-18 | Nutri-Fuels Systems, Inc. | Nutritional composition for enhancing skeletal muscle adaptation to exercise training |
DE3512054A1 (en) | 1985-04-02 | 1986-10-02 | HERMES Fabrik pharmazeutischer Präparate Franz Gradinger Gmbh & Co, 8023 Großhesselohe | PHARMACEUTICAL PREPARATION |
US4824669A (en) | 1985-04-11 | 1989-04-25 | Board Of Regents, The University Of Texas System | Formulations of coenzyme Q10 for intravenous use |
US5030458A (en) | 1989-11-27 | 1991-07-09 | Shug Austin L | Method for preventing diet-induced carnitine deficiency in domesticated dogs and cats |
AU8230687A (en) | 1986-10-23 | 1988-05-25 | Arval S.P.A. | Cosmetic preparations containing ubidecarenones |
DE3880923T3 (en) | 1987-02-23 | 1997-12-18 | Shiseido Co Ltd | PERCUTANE ABSORPTION PROMOTOR AND DERMATOLOGICAL COMPOSITION FOR EXTERNAL USE. |
US4871718A (en) | 1987-12-29 | 1989-10-03 | Raymond A. Roncari | Composition of matter for increasing intracellular ATP levels and physical performance levels and for increasing the rate of wound repair |
US5290605A (en) | 1989-06-29 | 1994-03-01 | Niva Shapira | Sun-exposure nutritional supporting composition |
US5532002A (en) | 1989-08-17 | 1996-07-02 | Cortecs Limited | Gelatin pharmaceutical formulations |
US5711950A (en) | 1990-01-12 | 1998-01-27 | Lorenzen; Lee H. | Process for preparing microclustered water |
US6300362B1 (en) * | 1990-07-25 | 2001-10-09 | Novartis Ag (Formerly Sandoz Ltd.) | Stabilized pharmaceutical compositions comprising acid donors |
US5310578A (en) | 1990-09-17 | 1994-05-10 | Merck Patent Gesellschaft | Deposition of cosmetically functional material onto pigments and fillers |
US5298246A (en) | 1991-01-09 | 1994-03-29 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Stable pharmaceutical composition and method for its production |
US5378461A (en) * | 1991-07-12 | 1995-01-03 | Neigut; Stanley J. | Composition for the topical treatment of skin damage |
CA2124086A1 (en) | 1991-11-22 | 1993-05-27 | Ronald H. Lane | Tocotrienols and tocotrienol-like compounds and methods for their use |
US5240961A (en) | 1992-07-02 | 1993-08-31 | Shug Austin L | Method of treating reduced insulin-like growth factor and bone loss associated with aging |
US5756291A (en) * | 1992-08-21 | 1998-05-26 | Gilead Sciences, Inc. | Aptamers specific for biomolecules and methods of making |
US5362753A (en) | 1993-04-19 | 1994-11-08 | Lonza Ltd. | Method of increasing the hatchability of eggs by feeding hens carnitine |
US5431916A (en) | 1993-04-29 | 1995-07-11 | The Procter & Gamble Company | Pharmaceutical compositions and process of manufacture thereof |
US6218436B1 (en) | 1993-06-28 | 2001-04-17 | The Howard Foundation | Pharmaceutically active carotenoids |
DE4327063A1 (en) | 1993-08-12 | 1995-02-16 | Kirsten Dr Westesen | Ubidecarenone particles with modified physicochemical properties |
US6054136A (en) | 1993-09-30 | 2000-04-25 | Gattefosse S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
US5438042B1 (en) | 1993-10-08 | 1997-08-26 | Sandoz Nutrition Ltd | Enteral nutritional composition having amino acid profile |
FR2714598B1 (en) | 1993-12-30 | 1996-02-09 | Oreal | Slimming composition with two types of liposomes for topical treatment, its use. |
GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
DE4410238A1 (en) | 1994-03-25 | 1995-09-28 | Beiersdorf Ag | Skin care products |
ES2170143T3 (en) | 1994-04-07 | 2002-08-01 | Smithkline Beecham Plc | COMPOSITIONS THAT INCLUDE HALOFANTRINE IN A SPECIAL FORM. |
US5686491A (en) | 1994-09-14 | 1997-11-11 | Sigma-Tau Pharmaceuticals, Inc. | Infant formula |
US5512691A (en) | 1994-11-07 | 1996-04-30 | Eastman Chemical Company | Process for the production of tocopherol concentrates |
US5670320A (en) | 1994-11-14 | 1997-09-23 | Emory University | Detection of mitochondrial DNA mutation 14459 associated with dystonia and/or Leber's hereditary optic neuropathy |
DE19603402A1 (en) | 1995-02-24 | 1996-08-29 | Basf Ag | Soft gelatin capsules |
US5552167A (en) | 1995-05-05 | 1996-09-03 | Nabisco, Inc. | Rice bran oil antioxidant |
US5716928A (en) | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
US5626849A (en) | 1995-06-07 | 1997-05-06 | Reliv International, Inc. | Weight loss composition for burning and reducing synthesis of fats |
US5560928A (en) | 1995-06-23 | 1996-10-01 | Defelice; Stephen L. | Nutritional and/or dietary composition and method of using the same |
DE19537027A1 (en) | 1995-10-05 | 1997-04-10 | Beiersdorf Ag | Skin care product for old skin |
EP0893949B1 (en) | 1996-01-16 | 2005-04-27 | Ronald J. Sokol | Use of antioxidant agents to treat cholestatic liver disease |
US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
US5948443A (en) | 1996-02-23 | 1999-09-07 | Medical Doctor's Research Institute, Inc. | Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease |
US6056971A (en) | 1996-07-24 | 2000-05-02 | Biosytes Usa, Inc. | Method for enhancing dissolution properties of relatively insoluble dietary supplements and product incorporating same |
KR980008239A (en) | 1996-07-26 | 1998-04-30 | 김충환 | Cyclosporin-containing pharmaceutical composition |
US6579854B1 (en) | 1996-08-14 | 2003-06-17 | Vanderbilt University | Diagnosis and management of infection caused by chlamydia |
JP3889481B2 (en) | 1996-08-16 | 2007-03-07 | 株式会社カネカ | Pharmaceutical composition |
US5891469A (en) | 1997-04-02 | 1999-04-06 | Pharmos Corporation | Solid Coprecipitates for enhanced bioavailability of lipophilic substances |
US5977162A (en) | 1996-09-16 | 1999-11-02 | Seidman; Michael D. | Therapeutic treatment for auditory function |
US5976568A (en) | 1997-02-21 | 1999-11-02 | Medical Doctors' Research Institute, Inc. | Modular system of dietary supplement compositions for optimizing health benefits and methods |
GB9704904D0 (en) | 1997-03-10 | 1997-04-30 | Riley Fletcher Foundation The | Essential oil composition |
ES2236891T3 (en) | 1997-03-12 | 2005-07-16 | Abbott Laboratories | HYDROFILE BINARY SYSTEMS FOR THE ADMINISTRATION OF CYCLOSPORINE. |
WO1998041195A2 (en) | 1997-03-20 | 1998-09-24 | Coventry Group, Ltd. | Nutritional supplement for cardiovascular health |
US6232346B1 (en) | 1997-03-27 | 2001-05-15 | Michael J. Sole | Composition for improvement of cellular nutrition and mitochondrial energetics |
US6080788A (en) | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
JP3926888B2 (en) | 1997-05-27 | 2007-06-06 | 株式会社カネカ | Cholesterol lowering agent |
AU7826798A (en) | 1997-06-09 | 1998-12-30 | Board Of Regents, The University Of Texas System | Superiority of formulations containing coenzyme q10 in coconut oil |
US6503483B2 (en) | 1997-06-12 | 2003-01-07 | C.S. Bioscience, Inc. | Dental formulation |
US6207137B1 (en) | 1997-06-12 | 2001-03-27 | C.S. Bioscience, Inc. | Dental formulation |
EP0888774A3 (en) * | 1997-06-30 | 1999-11-10 | Soft Gel Technologies, Inc. | Soft gel Coenzyme Q10 formulation |
US5985344A (en) | 1997-09-02 | 1999-11-16 | The Ricex Company | Process for obtaining micronutrient enriched rice bran oil |
JP4761093B2 (en) | 1997-12-10 | 2011-08-31 | シクロスポリン セラポイティクス リミテッド | Pharmaceutical composition comprising omega-3 fatty acid oil |
US6048846A (en) | 1998-02-26 | 2000-04-11 | Cochran; Timothy M. | Compositions used in human treatment |
US6503523B2 (en) | 1998-05-07 | 2003-01-07 | Gs Development A.B. | Skin care agents containing combinations of active agents consisting of vitamin a derivatives and UBI- or plastoquinones |
US6063432A (en) | 1998-05-19 | 2000-05-16 | Cooke Pharma | Arginine or lysine containing fruit healthbar formulation |
US6472378B2 (en) | 1998-08-31 | 2002-10-29 | Pro-Neuron, Inc. | Compositions and methods for treatment of mitochondrial diseases |
US6174547B1 (en) | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
US6048886A (en) | 1998-10-05 | 2000-04-11 | Neigut; Stanley | Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin |
US6277431B1 (en) | 1998-10-14 | 2001-08-21 | Redeem, Inc. | Anticholesterolemic edible oil |
US6200550B1 (en) | 1998-12-11 | 2001-03-13 | Q-Pharma, Inc. | Oral care compositions comprising coenzyme Q10 |
US6020383A (en) | 1999-01-11 | 2000-02-01 | Eastman Chemicals Company | Method for reducing blood cholesterol and/or blood triglycerides |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6258380B1 (en) | 1999-03-05 | 2001-07-10 | Banner Pharmacaps, Inc. | Chewable soft capsule |
US6616942B1 (en) | 1999-03-29 | 2003-09-09 | Soft Gel Technologies, Inc. | Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing |
US6368618B1 (en) | 1999-07-01 | 2002-04-09 | The University Of Georgia Research Foundation, Inc. | Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs |
US6479069B1 (en) | 1999-09-23 | 2002-11-12 | Juvenon, Inc. | Nutritional supplement for increased energy and stamina |
US6562869B1 (en) | 1999-09-23 | 2003-05-13 | Juvenon, Inc. | Nutritional supplement for increased energy and stamina |
US6528042B1 (en) | 1999-10-08 | 2003-03-04 | Galileo Laboratories, Inc. | Compositions of flavonoids for use as cytoprotectants and methods of making and using them |
US6426362B1 (en) | 1999-10-08 | 2002-07-30 | Galileo Laboratories, Inc. | Formulations of tocopherols and methods of making and using them |
US6455589B1 (en) | 1999-10-28 | 2002-09-24 | The Regents Of The University Of California | Primary N-hydroxylamines |
JP2003513039A (en) | 1999-11-03 | 2003-04-08 | ジュヴェノン インコーポレイテッド | How to treat benign amnesia |
US6716451B1 (en) | 1999-11-30 | 2004-04-06 | Soft Gel Technologies, Inc. | Formulation and delivery method to enhance antioxidant potency of vitamin E |
US8753675B1 (en) | 2000-01-20 | 2014-06-17 | Raj K. Chopra | Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications |
US6740338B1 (en) | 2000-01-20 | 2004-05-25 | Raj K. Chopra | Reduced form of Cenzyme Q in high bioavailability stable oral dosage form |
AU774311B2 (en) | 2000-01-31 | 2004-06-24 | Lab21, Inc. | Method and system for producing customized cosmetic and pharmaceutical formulations on demand |
US6664287B2 (en) | 2000-03-15 | 2003-12-16 | Bethesda Pharmaceuticals, Inc. | Antioxidants |
US6365181B1 (en) | 2000-04-20 | 2002-04-02 | Gattefosse Corporation | Thixatropic gelatin carrier composition |
CN1244561C (en) | 2000-05-11 | 2006-03-08 | 布里斯托尔-迈尔斯斯奎布公司 | Tetrahydroixoquinoline analogs useful as growth hormone secretagogues |
JP5259905B2 (en) | 2000-06-20 | 2013-08-07 | エヌ・ブイ・ニュートリション・サイエンシス | Medium chain fatty acids applicable as antibacterial agents |
US6623734B2 (en) | 2000-06-22 | 2003-09-23 | Soft Gel Technologies, Inc. | Super absorption coenzyme Q10 |
DE10038640A1 (en) * | 2000-07-28 | 2002-02-14 | Steigerwald Arzneimittelwerk | A preparation with vascular protective and antioxidative effects and its use |
US6545184B1 (en) | 2000-08-15 | 2003-04-08 | The Regents Of The University Of California | Practical, cost-effective synthesis of COQ10 |
US6441050B1 (en) | 2000-08-29 | 2002-08-27 | Raj K. Chopra | Palatable oral coenzyme Q liquid |
US6342526B1 (en) | 2000-09-18 | 2002-01-29 | Lonza Ltd. | Method for enhancing or achieving training-induced bradycardia with Carnitine |
US6552004B1 (en) | 2000-10-30 | 2003-04-22 | Universite De Montreal | Delivery system for entrapping charged macromolecules and a method for preparing same |
US6790465B2 (en) | 2000-12-01 | 2004-09-14 | Snore-Fix, Inc. | Composition and method for treating snoring |
US6855733B2 (en) | 2001-01-24 | 2005-02-15 | Soft Gel Technologies, Inc. | Formulation and manufacturing process for coenzyme Q10 soft gel capsules |
US20020098172A1 (en) | 2001-01-24 | 2002-07-25 | Udell Ronald G. | Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing |
US6300377B1 (en) | 2001-02-22 | 2001-10-09 | Raj K. Chopra | Coenzyme Q products exhibiting high dissolution qualities |
US6630170B2 (en) | 2001-04-26 | 2003-10-07 | Board Of Regents The University Of Texas System | Mesoporous compositions and method of preparation |
US6730319B2 (en) | 2001-06-06 | 2004-05-04 | Hoffmann-La Roche Inc. | Pharmaceutical compositions having depressed melting points |
US6506915B1 (en) | 2001-06-14 | 2003-01-14 | Daniel David West | Synthesis of coenzyme Q10 ubiquinone |
US6436431B1 (en) | 2001-07-02 | 2002-08-20 | Diane Wright Hoffpauer | Fortified rice bran food product and method for promoting cardiovascular health |
US20030044474A1 (en) | 2001-08-03 | 2003-03-06 | Shaklee Corporation | High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability |
JP3549197B2 (en) | 2001-08-10 | 2004-08-04 | 日清ファルマ株式会社 | Ubiquinone-containing preparations |
US6503506B1 (en) | 2001-08-10 | 2003-01-07 | Millenium Biotechnologies, Inc. | Nutrient therapy for immuno-compromised patients |
JP2003055204A (en) | 2001-08-21 | 2003-02-26 | Sansho Iyaku Kk | Ubidecarenone composition and capsule comprising the composition as content |
US20030082168A1 (en) | 2001-10-22 | 2003-05-01 | Inna Yegorova | Compositions and methods for facilitating weight loss |
AU2002343555A1 (en) | 2001-11-14 | 2003-05-26 | Texas Tech University | Eutectic-based self-nanoemulsified drug delivery system |
US6806259B2 (en) | 2001-12-21 | 2004-10-19 | Soft Gel Technologies, Inc. | Hyaluronic Acid in soft gel form |
US20030190343A1 (en) | 2002-03-05 | 2003-10-09 | Pfizer Inc. | Palatable pharmaceutical compositions for companion animals |
DE60319355T3 (en) | 2002-04-25 | 2012-01-05 | Banner Pharmacaps Inc. | CHICKEN SOAP CAPSULES |
JP4226846B2 (en) | 2002-06-07 | 2009-02-18 | キャタレント・ジャパン株式会社 | Soft capsule that can disintegrate in the oral cavity |
US7182950B2 (en) * | 2002-06-12 | 2007-02-27 | Nutralease Ltd. | Nano-sized self-assembled liquid dilutable vehicles |
US20040001874A1 (en) * | 2002-06-24 | 2004-01-01 | Vital Living, Inc. | Safe and effective nutritional supplement formulations and associated regimens adapted to prevent and/or treat targeted diseases or medical or health conditions, and related methods |
WO2004017916A2 (en) | 2002-08-22 | 2004-03-04 | 4Life Research, Lc | Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition |
FR2850275B1 (en) | 2003-01-24 | 2005-04-08 | Scherer Technologies Inc R P | SOFT MACHINE CAPSULES CONTAINING AN ACTIVE ACTIVE SUBSTANCE WITH MASK TASTE |
RU2006101991A (en) * | 2003-06-25 | 2006-06-27 | Чарлз ЭРВИН (US) | CHEMICAL COMPOSITION AND METHOD FOR INCREASING THE PROVISION OF CO-ENZYME Q10 |
US20080089877A1 (en) | 2003-08-14 | 2008-04-17 | Udell Ronald G | Super Absorption Coenzyme Q10 |
US8105583B2 (en) | 2003-09-29 | 2012-01-31 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
US8124072B2 (en) * | 2003-09-29 | 2012-02-28 | Soft Gel Technologies, Inc. | Solubilized CoQ-10 |
US7169385B2 (en) * | 2003-09-29 | 2007-01-30 | Ronald G. Udell | Solubilized CoQ-10 and carnitine |
CN1933824A (en) | 2004-03-23 | 2007-03-21 | 株式会社钟化 | Coenzyme q compositions persisting in blood |
US20080020022A1 (en) | 2006-06-05 | 2008-01-24 | Udell Ronald G | Chewable co-enzyme q-10 capsule |
US8343541B2 (en) | 2007-03-15 | 2013-01-01 | Soft Gel Technologies, Inc. | Ubiquinol and alpha lipoic acid compositions |
JP5770815B2 (en) | 2013-11-01 | 2015-08-26 | 云辰電子開發股▲分▼有限公司 | Wireless monitoring control method and apparatus |
-
2003
- 2003-09-29 US US10/674,268 patent/US8124072B2/en not_active Expired - Lifetime
-
2004
- 2004-09-29 JP JP2006528309A patent/JP4758898B2/en active Active
-
2005
- 2005-09-09 US US11/223,718 patent/US8147826B2/en not_active Expired - Lifetime
-
2006
- 2006-03-29 IL IL174624A patent/IL174624A/en active IP Right Grant
-
2012
- 2012-02-02 US US13/365,244 patent/US8617541B2/en not_active Expired - Lifetime
- 2012-02-28 US US13/406,794 patent/US8506859B2/en not_active Expired - Lifetime
-
2013
- 2013-08-13 US US13/966,063 patent/US8865032B2/en not_active Expired - Lifetime
- 2013-12-27 US US14/141,968 patent/US8932584B2/en not_active Expired - Lifetime
-
2014
- 2014-09-16 US US14/487,187 patent/US20150004304A1/en not_active Abandoned
- 2014-12-10 US US14/565,679 patent/US20150216807A1/en not_active Abandoned
-
2015
- 2015-07-28 US US14/811,018 patent/US20160184238A1/en not_active Abandoned
-
2016
- 2016-08-05 US US15/229,750 patent/US10166192B2/en not_active Expired - Lifetime
- 2016-11-23 US US15/359,912 patent/US10166193B2/en not_active Expired - Lifetime
-
2018
- 2018-11-20 US US16/196,644 patent/US20190192443A1/en not_active Abandoned
- 2018-11-20 US US16/196,296 patent/US20190091157A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20060013888A1 (en) | 2006-01-19 |
US20140112900A1 (en) | 2014-04-24 |
US20160184238A1 (en) | 2016-06-30 |
JP4758898B2 (en) | 2011-08-31 |
US20190192443A1 (en) | 2019-06-27 |
US20050070611A1 (en) | 2005-03-31 |
US10166193B2 (en) | 2019-01-01 |
US8617541B2 (en) | 2013-12-31 |
US8124072B2 (en) | 2012-02-28 |
US8932584B2 (en) | 2015-01-13 |
US8506859B2 (en) | 2013-08-13 |
US8147826B2 (en) | 2012-04-03 |
US20150004304A1 (en) | 2015-01-01 |
US20120153519A1 (en) | 2012-06-21 |
IL174624A (en) | 2014-09-30 |
US20170296473A1 (en) | 2017-10-19 |
US20120128769A1 (en) | 2012-05-24 |
IL174624A0 (en) | 2006-08-20 |
US20190091157A1 (en) | 2019-03-28 |
US8865032B2 (en) | 2014-10-21 |
US20170119697A1 (en) | 2017-05-04 |
JP2007507427A (en) | 2007-03-29 |
US10166192B2 (en) | 2019-01-01 |
US20130330405A1 (en) | 2013-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10166193B2 (en) | Method of making a soft gel capsule comprising CoQ-10 solubilized in a monoterpene | |
US7713523B2 (en) | Solubilized CoQ-10 and carnitine | |
US10314793B2 (en) | Solubilized CoQ-10 | |
US20080020022A1 (en) | Chewable co-enzyme q-10 capsule |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |